Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caiwei Zhong

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Genitourinary Cancer|March 27, 2026
Monitoring of Disease in Patients Receiving <sup>177</sup>LU-PSMA-617 Therapy in Routine PracticeNarmeen S Rashid, Caiwei Zhong, Wanling Xie, et al.
Prostate Cancer and Prostatic Diseases|November 18, 2025
Publisher Correction: Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancerAutumn Gagnon, Caiwei Zhong, Wanling Xie, et al.
Prostate Cancer and Prostatic Diseases|October 28, 2025
Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancerAutumn Gagnon, Caiwei Zhong, Wanling Xie, et al.
JCO Oncology Practice|April 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDaniel Sentana-Lledo, Avina Rami, Caiwei Zhong, et al.
Cancers|June 26, 2025
Race and Outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in Advanced Prostate CancerAvina Rami, Caiwei Zhong, Miguel Muniz, et al.
European Urology Oncology|November 15, 2024
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate CancerPraful Ravi, Caiwei Zhong, Wanling Xie, et al.
European Urology Focus|December 8, 2024
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell CarcinomaJustine Panian, Caiwei Zhong, Sharon H Choi, et al.
Nature Medicine|January 7, 2026
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinomaCarolina Alves Costa Silva, Marc Machaalani, Renee Maria Saliby, et al.
JACC. Cardiooncology|March 21, 2024
Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective StudyAmin H Nassar, Edward El-Am, Ryan Denu, et al.
Journal for Immunotherapy of Cancer|March 6, 2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromesAmin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Genitourinary Cancer|March 27, 2026
Monitoring of Disease in Patients Receiving <sup>177</sup>LU-PSMA-617 Therapy in Routine PracticeNarmeen S Rashid, Caiwei Zhong, Wanling Xie, et al.
Prostate Cancer and Prostatic Diseases|November 18, 2025
Publisher Correction: Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancerAutumn Gagnon, Caiwei Zhong, Wanling Xie, et al.
Prostate Cancer and Prostatic Diseases|October 28, 2025
Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancerAutumn Gagnon, Caiwei Zhong, Wanling Xie, et al.
JCO Oncology Practice|April 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDaniel Sentana-Lledo, Avina Rami, Caiwei Zhong, et al.
Cancers|June 26, 2025
Race and Outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in Advanced Prostate CancerAvina Rami, Caiwei Zhong, Miguel Muniz, et al.
European Urology Oncology|November 15, 2024
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate CancerPraful Ravi, Caiwei Zhong, Wanling Xie, et al.
European Urology Focus|December 8, 2024
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell CarcinomaJustine Panian, Caiwei Zhong, Sharon H Choi, et al.
Nature Medicine|January 7, 2026
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinomaCarolina Alves Costa Silva, Marc Machaalani, Renee Maria Saliby, et al.
JACC. Cardiooncology|March 21, 2024
Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective StudyAmin H Nassar, Edward El-Am, Ryan Denu, et al.
Journal for Immunotherapy of Cancer|March 6, 2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromesAmin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, et al.
Pageof 1